Ieq Capital, LLC Allogene Therapeutics, Inc. Transaction History

Ieq Capital, LLC

$32.2 Billion
Q3 2025

A detailed history of Ieq Capital, LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Ieq Capital, LLC holds 376,058 shares of ALLO stock, worth $462,551. This represents 0.0% of its overall portfolio holdings.

Number of Shares

376,058

Previous 186,178 101.99%

Holding current value

$462,551

Previous $210,000 121.9%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$1.03 - $1.66 $195,576 - $315,200	189,880 Added 101.99%	376,058 $466,000
Q2 2025 Aug 14, 2025	BUY	$0.95 - $1.7 $114,000 - $204,000	120,000 Added 181.33%	186,178 $210,000
Q2 2024 Aug 12, 2024	SELL	$2.23 - $4.38 $390 - $766	-175 Reduced 0.26%	66,178 $154,000
Q4 2023 Feb 07, 2024	BUY	$2.28 - $3.5 $398 - $612	175 Added 0.26%	66,353 $212,000
Q3 2023 Nov 03, 2023	BUY	$3.17 - $5.96 $65,454 - $123,062	20,648 Added 45.35%	66,178 $209,000

Q2 2023 Aug 07, 2023	BUY	$4.53 - $6.74 $11,460 - $17,052	2,530 Added 5.88%	45,530 $226,000
Q1 2023 May 01, 2023	BUY	$4.92 - $8.21 $103,320 - $172,410	21,000 Added 95.45%	43,000 $212,000
Q4 2022 Feb 03, 2023	SELL	$5.62 - $11.11 $118,020 - $233,310	-21,000 Reduced 48.84%	22,000 $138,000
Q4 2021 Jan 31, 2022	SELL	$13.13 - $24.52 $617 - $1,152	-47 Reduced 0.11%	43,000 $642,000
Q3 2021 Nov 09, 2021	BUY	$21.01 - $27.64 $987 - $1,299	47 Added 0.11%	43,047 $1.11 Million
Q4 2019 Feb 04, 2020	BUY	$24.82 - $31.4 $1.07 Million - $1.35 Million	43,000 New	43,000 $1.12 Million

Others Institutions Holding ALLO

# of Institutions

182

Shares Held

138M

Call Options Held

76.6K

Put Options Held

36.2K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $177M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ieq Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ieq Capital, LLC with notifications on news.

Account